- Home
- RIGL vs ALLT Comparison
RIGL vs ALLT Comparison
Compare RIGL & ALLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | ALLT |
|---|---|---|
| Founded | 1996 | 1996 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 537.6M | 429.1M |
| IPO Year | 2000 | 2006 |
Fundamental Metrics
Financial Performance| Metric | RIGL | ALLT |
|---|---|---|
| Price | $43.40 | $9.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $43.20 | $12.75 |
| AVG Volume (30 Days) | ★ 654.6K | 441.1K |
| Earning Date | 11-04-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2698.26 | N/A |
| EPS | ★ 6.20 | 0.02 |
| Revenue | ★ $282,076,000.00 | $98,512,000.00 |
| Revenue This Year | $65.53 | $12.44 |
| Revenue Next Year | $0.22 | $12.98 |
| P/E Ratio | ★ $7.00 | $460.34 |
| Revenue Growth | ★ 79.13 | 7.51 |
| 52 Week Low | $14.63 | $4.37 |
| 52 Week High | $52.24 | $11.42 |
Technical Indicators
Market Signals| Indicator | RIGL | ALLT |
|---|---|---|
| Relative Strength Index (RSI) | 52.26 | 60.06 |
| Support Level | $43.81 | $9.07 |
| Resistance Level | $49.96 | $10.14 |
| Average True Range (ATR) | 3.82 | 0.49 |
| MACD | -0.53 | 0.09 |
| Stochastic Oscillator | 33.11 | 82.47 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About ALLT Allot Ltd.
Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. The company has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.